# A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias

> **NCT07491172** · PHASE1 · RECRUITING · sponsor: **CRISPR Therapeutics AG** · enrollment: 90 (estimated)

## Conditions studied

- Cardiovascular
- Metabolic Disease
- Dyslipidemias
- Lipid Disorder
- Hypertriglyceridemia
- Heterozygous Familial Hypercholesterolemia (HeFH)
- Homozygous Familial Hypercholesterolemia (HoFH)
- Severe Hypertriglyceridemia (sHTG)
- Mixed Hyperlipemia
- Hypercholesterolaemia

## Interventions

- **DRUG:** CTX310

## Key facts

- **NCT ID:** NCT07491172
- **Lead sponsor:** CRISPR Therapeutics AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-21
- **Primary completion:** 2027-06
- **Final completion:** 2028-06
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07491172

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07491172, "A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT07491172. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*